To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Brain | Neurodegenerative diseases
The group of Marc Dhenain (MIRCen) has developed an MRI microscopy technique that can track in vivo the fate of amyloid plaques. This technique was used to characterize an immunotherapy targeting specific forms of amyloid (called protofibrillar). The article, published in collaboration with Sanofi, demonstrates an effective partnership between the CEA and industrial partners.
Alzheimer's disease is characterized by microscopic lesions called "amyloid plaques". They appear up to 20 years before the clinical signs of the disease. Anti-amyloid immunotherapies are therapies that aim to mobilize the immune system to fight against these lesions. How to determine the effectiveness of these new treatments?
The group of Marc Dhenain (Multimodal Imaging of Neurodegenerative Diseases and Therapies, MIRCen) has developed an MRI microscopy technique that can track in vivo the fate of amyloid plaques. This technique was used to characterize an immunotherapy targeting specific forms of amyloid (called protofibrillar). The results of this study were published in March 2016 in the journal Frontiers in Aging Neuroscience. This is the first article presenting an MRI method allowing to follow the fate of individual amyloid plaques over time. It demonstrated that amyloid plaques are extremely stable lesions that never disappear spontaneously. MRI scans revealed that the tested therapy prevents the formation of amyloid plaques and helped to better characterize the mechanisms of action of this therapy. The article, published in collaboration with Sanofi, demonstrates an effective partnership between the CEA and industrial partners. It follows previous studies where the group of Marc Dhenain characterized the lack of toxicity of this therapy and where Thierry Delzescaux, another researcher of the team, revealed the beneficial effects of this immunotherapy with innovative 3D histology markers (published in April 2016 in Scientific Reports). Since the end of the study, the tested immunotherapy has been passed in clinical study in humans. The developed MRI method continues to be improved in order to be tested in animals and humans.
In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy.Santin, M. D., M. E. Vandenberghe, A. S. Herard, L. Pradier, C. Cohen, T. Debeir, T. Delzescaux, T. Rooney and M. Dhenain (2016). Front Aging Neurosci 8: 55.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.